ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proudly contributing to breakthrough research discoveries around the world. In October 2020 ChromoTek was acquired by Proteintech Group. The combined companies will better address the industry’s growing opportunities. Founded in 2008, ChromoTek continues to grow its business in Martinsried.

A creative mindset, the passion for science and the belief in innovation as a motor for the greater good make me tick. I like to challenge traditional approaches. Hence, I am attracted to proceed applying less conventional methods and yet taking advantage of learning and observing from others. No one has ever accomplished before, what the scientific founding team of ChromoTek has realized. I want to keep their vision alive and I am proud how far we have come; however, the next challenges are already waiting. It is a rare privilege to have such a creative working environment with a team that gets energized the more difficult the resolution of a problem seems to be. Above all, there is the desire to contribute with our work to the long and risky value chain that ultimately improves our health.